Maravai Lifesciences Holdings, Inc. (MRVI) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Maravai Lifesciences’s revenue went from $143M in fiscal 2019 to $186M in fiscal 2025, growth of about 4.4% a year.
Net income in fiscal 2025 was -$131M, a net margin of -70.4%; the best year in this period was 2022 with $220M.
Over the twelve months to September 30, 2026, revenue was $213M and net income -$66M.
Free cash flow was -$71M in fiscal 2025 and positive in 5 of the 7 years shown.
The diluted share count fell 43% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213M | $186M | $259M | $289M | $883M | $799M | $284M | $143M |
| Gross profit | $83M | $34M | $108M | $140M | $714M | $659M | $204M | $76M |
| Operating income | -$97M | -$215M | -$236M | -$32M | $574M | $555M | $120M | $24M |
| Net income | -$66M | -$131M | -$145M | -$119M | $220M | $182M | $89M | -$4M |
| EPS (diluted) | $-0.43 | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 | $-0.03 |
| R&D | $15M | $17M | $19M | $17M | $18M | $15M | $9M | $4M |
| Revenue growth | — | −28.3% | −10.3% | −67.3% | +10.5% | +181.3% | +98.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5M | -$58M | $7M | $126M | $536M | $369M | $152M | $24M |
| Capital spending | -$8M | -$13M | -$30M | -$66M | -$17M | -$15M | -$25M | -$17M |
| Free cash flow | -$13M | -$71M | -$22M | $61M | $519M | $354M | $127M | $7M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | $0 | $0 | $34M | $0 |
| Stock-based pay | $31M | $30M | $49M | $35M | $19M | $10M | $25M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $217M | $322M | $575M | $632M | $551M | $236M | $25M |
| Debt | — | $334M | $345M | $578M | $585M | $575M | $535M | — |
| Equity | — | $212M | $325M | $417M | $545M | $315M | $89M | $145M |
| Total assets | — | $771M | $1.0B | $1.5B | $2.3B | $1.9B | $1.3B | — |
| Shares (diluted) | — | 144M | 138M | 132M | 255M | 258M | 29M | 254M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 39.1% | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% |
| Operating margin | -45.4% | -115.9% | -90.9% | -10.9% | 65.0% | 69.4% | 42.2% | 16.8% |
| Net margin | -30.8% | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% |
| FCF margin | -6.2% | -38.1% | -8.6% | 21.0% | 58.8% | 44.3% | 44.6% | 4.9% |
| ROIC | — | -38.7% | -34.9% | -2.5% | 45.2% | 55.0% | 18.6% | 14.7% |
| ROE | — | -61.6% | -44.5% | -28.6% | 40.4% | 57.7% | 100.5% | -3.1% |
Frequently asked questions
What is Maravai Lifesciences’s annual revenue?
$186M in fiscal 2025 and $213M over the twelve months to September 30, 2026.
How much profit does Maravai Lifesciences make?
Net income was -$131M in fiscal 2025 (net margin -70.4%).
Is Maravai Lifesciences’s revenue growing?
No: revenue fell 28.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.